PET Brain Metabolism May Help Personalize Alzheimer's

How Could PET Brain Metabolism Predict Alzheimer's Treatment Response?

The new report, highlighted by the Society of Nuclear Medicine and Molecular Imaging, focuses on PET imaging patterns in people who received Alzheimer's disease treatment. Instead of looking only at amyloid plaques or tau tangles, the work examines brain metabolism, which is commonly assessed with FDG-PET and reflects regional glucose use in the brain.

This matters because Alzheimer's disease is not biologically identical in every patient. Two people may have similar memory symptoms but different degrees of synaptic dysfunction, vascular disease, inflammation or mixed dementia pathology. A metabolic PET pattern that identifies likely responders could help clinicians move from a one-size-fits-all approach toward treatment decisions based on the living brain's functional state.

Why Does This Matter For New Alzheimer's Drugs?

FDA-approved anti-amyloid antibodies such as lecanemab and donanemab are intended for early Alzheimer's disease in patients with evidence of amyloid pathology. Clinical trials published in major journals showed slower cognitive and functional decline compared with placebo, but these treatments do not reverse dementia and are not appropriate for every person with memory loss.

Patient selection is especially important because antibody treatments require infusion schedules, biomarker testing and MRI monitoring for amyloid-related imaging abnormalities, known as ARIA. If PET metabolism can help identify who is more likely to benefit, it could reduce unnecessary exposure to treatment burden and focus specialist care on patients with the best chance of meaningful response.

Should Patients Ask For A PET Scan Before Alzheimer's Treatment?

For patients and families, the practical message is cautious optimism. PET imaging is already used in dementia evaluation in selected cases, including amyloid PET, tau PET in research settings and FDG-PET for patterns of neurodegeneration. However, using metabolic PET specifically to predict treatment benefit is not yet a routine standard of care.

The next step is prospective research showing that treatment decisions guided by metabolic PET actually improve outcomes. Until then, evaluation should remain comprehensive: clinical history, cognitive testing, medication review, MRI when appropriate, laboratory assessment for reversible contributors and validated Alzheimer's biomarker testing when disease-modifying therapy is being considered.